Sermorelin is a synthetic 29-amino-acid peptide that corresponds to the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). Natural GHRH is 44 amino acids long, but structure-activity work in the 1980s established that the first 29 residues contain essentially all of the receptor-binding and bioactive information. Sermorelin engages the GHRH receptor (GHRH-R) on pituitary somatotroph cells and signals those cells to release stored growth hormone. It was FDA-approved in 1997 for pediatric growth hormone deficiency under the brand name Geref, later withdrawn from the market for commercial reasons, and continues today as a research peptide and in some clinical-research contexts.

How does Sermorelin work mechanistically?

Sermorelin binds the GHRH receptor on the surface of pituitary somatotroph cells. The receptor is a class B G-protein-coupled receptor that couples primarily to Gs, activating adenylyl cyclase and raising intracellular cAMP. The cAMP signal activates protein kinase A, which phosphorylates downstream targets including CREB, increasing growth hormone gene transcription and triggering exocytosis of stored growth hormone granules. The result is pulsatile release of growth hormone into the systemic circulation. Sermorelin does not act in place of growth hormone; it acts one step upstream, signaling the cells that make growth hormone to release what they have already synthesized.

What is the relationship between Sermorelin and natural GHRH?

Sermorelin is essentially the natural GHRH sequence truncated after residue 29. Natural GHRH is 44 amino acids long, but the C-terminal residues 30-44 contribute only modestly to receptor binding. Sermorelin retains essentially full receptor agonist activity despite the truncation, which is why it is described as the 'minimum bioactive GHRH.' The truncation does, however, mean Sermorelin shares the same DPP-4 vulnerability and short half-life as natural GHRH — a feature that later GHRH analogs (CJC-1295, Tesamorelin) were specifically designed to address.

What is the half-life of Sermorelin?

Sermorelin has a short plasma half-life on the order of minutes, dominated by rapid cleavage by dipeptidyl peptidase-4 (DPP-4) between residues Ala-2 and Asp-3. This produces an inactive GHRH(3-29) fragment that is no longer a receptor agonist. The short half-life is a characteristic feature of the natural GHRH sequence and contributes to the pulsatile pattern of growth hormone release that Sermorelin tends to produce. Longer-acting GHRH analogs — CJC-1295 with DAC has a half-life of roughly a week, Tesamorelin has a half-life of about 25-40 minutes — were designed specifically to overcome this short native half-life.

How is Sermorelin different from CJC-1295?

Both are GHRH receptor agonists, but they differ in stability and duration of action. Sermorelin is the natural GHRH(1-29) sequence with no modifications and a short minutes-scale half-life. CJC-1295 without DAC has four amino-acid substitutions (including D-Ala at position 2) that confer DPP-4 resistance but the overall half-life remains short. CJC-1295 with DAC adds a maleimide-based 'drug affinity complex' that covalently binds plasma albumin, extending the half-life to roughly a week and producing a sustained GHRH signal rather than a pulsatile one. The choice between these compounds in research reflects whether a brief, pulse-like GHRH stimulus or a sustained signal is desired.

How is Sermorelin different from Ipamorelin?

They act on different receptors. Sermorelin engages the GHRH receptor (GHRH-R), the natural target of hypothalamic GHRH. Ipamorelin engages the growth hormone secretagogue receptor (GHS-R), the natural target of ghrelin. Both pathways converge at the somatotroph cell to produce growth hormone release, but the upstream signaling, the susceptibility to somatostatin counterregulation, and the selectivity profile differ. The combination of a GHRH analog like Sermorelin with a GHS-R agonist like Ipamorelin is well-characterized in the literature as producing a synergistic growth hormone response — larger than either compound alone.

Why was the clinical product Geref withdrawn from the market?

Sermorelin under the brand name Geref was approved by the FDA in 1997 for treatment of pediatric growth hormone deficiency. The product was later withdrawn from the U.S. market by the manufacturer for commercial rather than safety reasons. By the time of withdrawal, recombinant human growth hormone had become the dominant treatment for pediatric growth hormone deficiency, and the commercial market for a hypothalamic releasing factor product was insufficient to sustain the approved product. The withdrawal did not reflect any newly identified safety concern with the compound itself. Sermorelin has continued since then as a research peptide and as a compounded preparation in some clinical-research contexts.

What is the GHRH receptor?

The GHRH receptor (GHRH-R) is a class B G-protein-coupled receptor expressed primarily on somatotroph cells of the anterior pituitary gland. It is the natural target of hypothalamic GHRH and is the receptor that Sermorelin engages. The receptor couples primarily to the Gs heterotrimeric G protein, activating adenylyl cyclase and raising intracellular cAMP when an agonist binds. The downstream cAMP signaling cascade increases growth hormone gene transcription and triggers exocytosis of stored growth hormone granules. The receptor has also been identified on cells outside the pituitary in some tissues, where its function is less well-characterized.

Does Sermorelin produce IGF-1 elevation?

Sermorelin indirectly engages the IGF-1 axis through the normal physiological cascade — by stimulating growth hormone release, which then acts on the growth hormone receptor in peripheral tissues including the liver to drive IGF-1 production. The magnitude of the IGF-1 response depends on the magnitude and pattern of the growth hormone release, which in turn depends on the dose, the prevailing somatostatin tone, and the integrity of the downstream growth hormone axis. The pulsatile pattern of Sermorelin-driven growth hormone release produces a different IGF-1 response profile than the sustained release produced by longer-acting GHRH analogs.

What is pulsatile growth hormone secretion?

Growth hormone is not released into the circulation at a constant rate. Instead, the somatotroph cells release growth hormone in discrete pulses, with major secretory pulses occurring during slow-wave sleep and smaller pulses occurring at intervals during the day. The pulsatile pattern is generated by the reciprocal oscillation of hypothalamic GHRH (stimulatory) and somatostatin (inhibitory). The pulsatile pattern is biologically important — many of the downstream effects of growth hormone signaling depend on the pulse pattern, not just the total amount of hormone released. Sermorelin, with its short half-life, tends to preserve the natural pulsatile pattern more closely than longer-acting GHRH analogs.

What is DPP-4 and why does it matter for Sermorelin?

Dipeptidyl peptidase-4 (DPP-4) is a serine protease that cleaves N-terminal dipeptides from peptide substrates that have an alanine or proline at the second position. The natural GHRH sequence has Ala-2, which makes the molecule a DPP-4 substrate. DPP-4 cleavage between Ala-2 and Asp-3 produces the GHRH(3-44) or GHRH(3-29) fragment, which is no longer an active GHRH receptor agonist. This cleavage is the major route of inactivation for both natural GHRH and Sermorelin, and it accounts for the short minutes-scale plasma half-life. Later GHRH analogs replace Ala-2 with D-Ala or other modifications that resist DPP-4 cleavage.

Is Sermorelin the same as somatotropin?

No. Somatotropin is another name for growth hormone — the 191-amino-acid pituitary protein that acts on the growth hormone receptor in peripheral tissues. Sermorelin is a 29-amino-acid hypothalamic releasing factor analog that acts on a completely different receptor (the GHRH receptor) and signals the pituitary to release growth hormone. The two are at different levels of the same axis: somatotropin is the hormone itself, Sermorelin is the upstream releasing signal.

What is the molecular weight of Sermorelin?

The molecular mass of Sermorelin in the free-acid form is approximately 3358 daltons. The C-terminal amide form (Arg-NH2 rather than Arg-OH) has a slightly lower mass — approximately 3357 daltons — reflecting the difference between the free carboxylic acid and the amide group at the C-terminus. The molecular mass is one of the parameters reported on a Certificate of Analysis for research-grade material, confirmed by mass spectrometry.

How is Sermorelin manufactured?

Research-grade Sermorelin is produced by solid-phase peptide synthesis using Fmoc protecting-group chemistry. The peptide is assembled residue by residue on a solid resin, then cleaved from the resin and deprotected. The crude peptide is purified by reversed-phase HPLC to remove truncated sequences, deletion sequences, and other synthesis byproducts, then lyophilized for storage. Identity is confirmed by mass spectrometry and purity is reported as a percentage based on HPLC peak area. The synthesis presents no unusual challenges for a peptide of this size, and reputable suppliers report purity in the 95-99% range for research-grade material.

What does a Certificate of Analysis report for Sermorelin?

A Certificate of Analysis for research-grade Sermorelin typically reports the peptide sequence, the measured molecular mass by mass spectrometry, the HPLC purity as a percentage of total peptide content, the residual moisture content of the lyophilized powder, the appearance of the lyophilized material, and the lot or batch number. Some certificates also report the absence of bacterial endotoxin (relevant for parenteral research preparations) and the residual acetate content (from the trifluoroacetate or acetate counterion typically present after purification). A complete certificate provides the traceability that a research protocol needs to document the identity and quality of the material used.

Is Sermorelin still used clinically?

The original approved product (Geref) was withdrawn from the U.S. market for commercial reasons, and Sermorelin is not currently marketed as an FDA-approved finished pharmaceutical product in the United States. The compound is, however, available in some jurisdictions as a compounded preparation prepared by licensed compounding pharmacies in response to specific clinical-research orders. Use of Sermorelin in those contexts is governed by the relevant clinical practice standards and regulatory frameworks in each jurisdiction. The research peptide form discussed on this page is a separate product intended for laboratory and analytical use only.

What is GHRH and where does it come from?

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide hormone produced by neurons in the arcuate nucleus of the hypothalamus. It is released into the hypothalamic-pituitary portal blood system and travels directly to the anterior pituitary gland, where it binds the GHRH receptor on somatotroph cells and stimulates growth hormone release. GHRH was first sequenced in 1982 from pancreatic tumor tissue that produced the peptide ectopically, and shortly afterward the same sequence was identified in human hypothalamus. The discovery completed the picture of hypothalamic releasing factors that had been worked out through the 1960s and 1970s for TRH, LHRH, and somatostatin.

What is the role of somatostatin in growth hormone regulation?

Somatostatin is a 14-amino-acid (or 28-amino-acid in a longer form) peptide hormone produced by neurons in the hypothalamus and by other tissues throughout the body. In the context of growth hormone regulation, hypothalamic somatostatin acts on the pituitary somatotroph cells through somatostatin receptors (sst1-sst5) and inhibits growth hormone release. The pulsatile pattern of growth hormone secretion is generated by the reciprocal oscillation of GHRH (stimulatory) and somatostatin (inhibitory) tone. Sermorelin's effects on growth hormone release are influenced by the prevailing somatostatin tone — when somatostatin tone is high, the Sermorelin response is blunted; when somatostatin tone is low, the response is larger.

Why are GHRH + GHRP combinations used in research?

GHRH analogs like Sermorelin and GHRP / GHS-R agonists like Ipamorelin engage two parallel upstream pathways that both converge on growth hormone release. When the two pathways are stimulated simultaneously, the resulting growth hormone response is typically larger than the sum of the two individual responses — a synergistic interaction. The mechanism involves both convergent intracellular signaling within the somatotroph cell and the suppression of somatostatin tone by the GHRP class. This synergism is one of the more characteristic findings in the secretagogue literature and is the basis for the common research practice of combining a GHRH analog with a GHRP / GHS-R agonist in protocols that aim to study maximal growth hormone release.

What storage and reconstitution practices apply to Sermorelin?

Lyophilized Sermorelin stored sealed at -20 °C or below away from light is generally considered stable for extended periods. For laboratory use, the lyophilized material is typically reconstituted in sterile bacteriostatic water (water containing 0.9% benzyl alcohol as a preservative) to produce a clear solution at a defined concentration. Reconstituted material stored at 2-8 °C is typically used within several weeks. To avoid repeated freeze-thaw cycles that could degrade the peptide, reconstituted material is sometimes aliquoted into single-use portions and stored frozen, with each aliquot thawed once for use. Care with methionine oxidation (avoiding air exposure) and with light exposure are standard for peptides of this kind.

Sermorelin (with Bacteriostatic Water) lyophilized vial with bacteriostatic water for research

Swiss-SourcedPharmaceutical-GradeLyophilized PowderIn Stock≥99% Purity

In Stock

Sermorelin (with Bacteriostatic Water)

Name: Sermorelin
Brand: Dr Jays Peptides
SKU: FC1851
Price: 40.00 USD
Availability: OutOfStock

In Stock — ships from Jacksonville, FL

Free shipping over $300 — you're $300.00 away

SKU: FC5049

$66.00

Volume pricing

·10 mg

Sitewide sale price — extra discount by quantity on this line

Quantity	Price / Unit	Discount
5–9	$62.70	5%
10–15	$59.40	10%
16–20	$56.10	15%
21+	$52.80	20%

Dosage10 mg

100% Satisfaction Guarantee — damaged, incorrect, or off-spec orders are made right with a free reship or refund.
Flat-rate 2-day shipping (when available) from Jacksonville, FL · free shipping insurance on every order · free over $300.
Bacteriostatic water included — the correct amount for reconstitution, in every order.
Sourced direct from our Swiss pharmaceutical-grade manufacturer · Batch-traceable · Veteran-owned · 20% of profits donated to animal charities.
Secure checkout — powered by Shopify.

Accepted:

ZelleStripeBankful

Research use only — not for human or veterinary consumption.

What you receive

Sealed, lyophilized vial — 10 mg
Bacteriostatic water — appropriate size for reconstitution, included free
Certificate of Analysis available — view COAs

Sermorelin is a synthetic research peptide studied in laboratory environments for its relevance to growth hormone releasing pathways, endocrine signalling mechanisms, and investigational models involving hormone regulation and cellular communication. It is commonly explored in controlled research settings focused on peptide-based signalling mechanisms and biochemical pathway analysis.

Growth Hormone ResearchEndocrine SignallingPeptide ResearchLyophilized

Swiss-sourced · Pharmaceutical-grade · Cold-chain shipped

What researchers say

Real reviews from Dr Jays Peptides customers

Why Dr Jays vs. the alternatives

An honest side-by-side for researchers who care about what's in the vial

Purity guarantee

Dr Jays

98%+ guaranteed

Others

95–97% claimed

COA included with every order

Dr Jays

Others

Refund if purity fails

Dr Jays

Others

Same-Day shipping UPS

Cold storage — temperature controlled

Dr Jays

Others

Responsive human support

email reply in under 30 minutes

Dr Jays

Others

100% American made & sourced

Synthesized & fulfilled in the USA

Dr Jays

Others

Veteran owned & operated

Dr Jays

Others

Criteria	Dr Jays Peptides	Other peptide vendors
Purity guarantee	98%+ guaranteed	95–97% claimed
COA included with every order		~
Refund if purity fails
Same-Day shipping UPS Cold storage — temperature controlled
Responsive human support email reply in under 30 minutes		~
100% American made & sourced Synthesized & fulfilled in the USA
Veteran owned & operated